GlassScriptPhysician profile
Julie P Delellis
NPI 1417469016
$4,360.52
in general payments reported to CMS, 2019-2025
25 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $885 · 2022: $1,099 · 2023: $976 · 2024: $401 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $714.11 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $706.22 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $516.64 | 2021-2023 | Xarelto |
| Pfizer INC. | $370.41 | 2021-2025 | |
| Abbott Laboratories | $356.01 | 2021-2022 | |
| Amgen INC. | $350.98 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $154.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $147.94 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.30 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $112.17 | 2023-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $94.42 | 2023-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $84.80 | 2023-2025 | Optimizer, Optimizer |
| Boston Scientific Corporation | $82.05 | 2024-2025 | Watchman Flx |
| Cvrx, INC. | $76.36 | 2025 | Barostim Neo System |
| Abiomed | $76.31 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $72.31 | 2022-2023 | Qdot Micro Catheter, Carto 3 |
| Edwards Lifesciences Corporation | $71.09 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals, LTD. | $49.64 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $40.16 | 2023 | |
| Philips North America LLC | $38.12 | 2024 | (Ao0) Igt Devices Intracardiac |
| Esperion Therapeutics, INC. | $28.35 | 2022-2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $24.22 | 2023 | Onpattro |
| Scpharmaceuticals INC. | $20.82 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.59 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.00 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Delellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.